PTX – Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated products that address unmet medical needs.
PTX – Pernix Therapeutics Holdings Inc
|Fundamentals||Previously closed at||0.75|
|Analysts opinion||Hedgefund Point 72, by Steve Cohen has apparently bought a 5.8% stake in PTX, which has raised the price of PTX to $1.5 Pre-market. The institutional ownership for Pernix therapeutics is high, at 63.99%. 12 funds opened new Pernix Therapeutics Holdings, Inc stakes, 39 increased stakes. There were 25 that closed positions and 34 reduced them. Two managers had the stock in their top Ten.
Also, technically, PTX has an RSI of 25.84, which suggests an entry point. Many Brokers, including Brean Capital, ING, Citigroup have a “Buy” rating for PTX. However, a number of firms like Zacks, have a “sell” rating. The target price varies from $3 to $8.
|Sentiments||Sentiments are positive for PTX, which is up +70.64% pre-market today. Sentiment index is 357.14% on the positive side on Stockal proprietary app, which suggests a further price rise.|
|Social Media Pulse||The stock has 100% higher chatter than usual.|